Exposure to entry inhibitors alters hiv infectiousness and sensitivity to broadly neutralizing monoclonal antibodies

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 1, 2014, Pages 7-14

  Kramer, Victor G ^a,b   Varsaneux, Olivia ^a,b   Oliviera, Maureen ^a   Colby Germinario, Susan P ^a   Mesplède, Thibault ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

antibodies; antiretrovirals; entry inhibitors; HIV; maraviroc; T 20

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MARAVIROC; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY PG9; MONOCLONAL ANTIBODY VRC01; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T LYMPHOCYTE; ULTRAFILTRATION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; HIV INFECTIONS; IC50; PHYSIOLOGY; REGRESSION ANALYSIS; SERODIAGNOSIS; VIROLOGY;

ANTIBODIES, MONOCLONAL; CELL LINE; CYCLOHEXANES; DRUG SYNERGISM; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; NEUTRALIZATION TESTS; REGRESSION ANALYSIS; TRIAZOLES; VIRUS REPLICATION;

EID: 84906084699     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000223     Document Type: Article

References (49)

1. Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis. 2003;37:1102-1106.
2. Hanna GJ, Lalezari J, Hellinger JA, et al. Antiviral activity, pharmaco-kinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Che-mother. 2011;55:722-728.
3. Nettles RE, Schurmann D, Zhu L, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012;206:1002-1011.
4. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721-4732.
5. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4: 72-77.
6. De Feo CJ, Weiss CD. Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses. 2012;4:3859-3911.
7. Grupping K, Selhorst P, Michiels J, et al. Mini CD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. Retrovirology. 2012;9:36.
8. Putcharoen O, Lee SH, Henrich TJ, et al. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol. 2012;86:1119-1128.
9. Tsibris AM, Hu Z, Paredes R, et al. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol. 2012;86:6416-6426.
10. Roche M, Jakobsen MR, Sterjovski J, et al. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol. 2011;85:4330-4342.
11. Pfaff JM, Wilen CB, Harrison JE, et al. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol. 2010;84:6505-6514.
12. Kramer VG, Siddappa NB, Ruprecht RM. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res. 2007;5:642-655.
13. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med. 2012;2:a007039.
14. Zhang Y, Yuan T, Li J, et al. The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development. AIDS. 2013;27:2529-2539.
15. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA. 2003;100:4144-4149.
16. Garcia-Perez J, Rueda P, Alcami J, et al. An allosteric model of maravir-oc binding to CCR5. J Biol Chem. 2011;286:33409-33421.
17. Tan Q, Zhu Y, Li J, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc Complex. Science. 2013;341:1387-1390.
18. Kramer VG, Schader SM, Oliveira M, et al. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother. 2012; 56:4154-4160.
19. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses. 1993;9:1051-1053.
20. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503:224-228.
21. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immuno-Therapy of macaques chronically infected with SHIV suppresses virae-mia. Nature. 2013;503:277-280.
22. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5: e1000433.
23. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492:118-122.
24. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS. 2003;17:301-309.
25. Horwitz JA, Halper-Stromberg A, Mouquet H, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA. 2013;110:16538-16543.
26. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005;11:615-622.
27. Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev. 2013;254:295-304.
28. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73:4009-4018.
29. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207-210.
30. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;6:200-206.
31. Hoxie JA. Toward an antibody-based HIV-1 vaccine. Annu Rev Med. 2010;61:135-152.
32. Lusso P, Cocchi F, Balotta C, et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995;69:3712-3720.
33. Platt EJ, Wehrly K, Kuhmann SE, et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:2855-2864.
34. Hwang SS, Boyle TJ, Lyerly HK, et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science. 1991; 253:71-74.
35. Freed EO, Englund G, Martin MA. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol. 1995;69:3949-3954.
36. Sastry L, Xu Y, Cooper R, et al. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum Gene Ther. 2004; 15:221-226.
37. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628.
38. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA. 2002;99:395-400.
39. Geonnotti AR, Bilska M, Yuan X, et al. Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma inter-feron production. AIDS Res Hum Retroviruses. 2010;26:279-291.
40. Daelemans D, Pauwels R, De Clercq E, et al. A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc. 2011;6:925-933.
41. Haim H, Si Z, Madani N, et al. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 2009;5:e1000360.
42. Zhu P, Liu J, Bess J Jr, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006;441:847-852.
43. Polzer S, Muller H, Schreiber M. Effects of mutations on HIV-1 infec-tivity and neutralization involving the conserved NNNT amino acid sequence in the gp120 V3 loop. FEBS Lett. 2009;583:1201-1206.
44. Scanlan CN, Pantophlet R, Wormald MR, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-.2 mannose residues on the outer face of gp120. J Virol. 2002;76:7306-7321.
45. Tran EE, Borgnia MJ, Kuybeda O, et al. Structural mechanism of tri-meric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012;8: e1002797.
46. Pugach P, Kuhmann SE, Taylor J, et al. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology. 2004;321:8-22.
47. Zwick MB, Jensen R, Church S, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycopro-tein gp41 to neutralize HIV-1. J Virol. 2005;79:1252-1261.
48. Haim H, Strack B, Kassa A, et al. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 2011;7:e1002101.
49. Picker LJ, Deeks SG. HIV: antibodies advance the search for a cure. Nature. 2013;503:207-208.